Close button
The Guardian
Email YouTube Facebook Instagram Twitter WhatsApp

May & Baker wants excellence in drug manufacturing




Officials of May and Baker Nigeria Limited have reiterated the need for pharmaceutical companies to be excellent in their drugs manufacturing in order to serve Nigerians better.

The officials, who spoke during a media launch in Ota, Ogun State, said the company is committed to quality products and that the company’s PharmaCentre was in 2014 certified by the World Health Organisation (WHO) for Good Manufacturing Practice (GMP).

They stated that excellence in manufacturing drugs would help to improve the Domestic Gross Product (GDP) of the country as well as improving the economy.

Managing Director and Chief Executive Officer of the company, Nnamdi Okafor, said May and Baker has done their best to ensure excellence in their drugs manufacturing as well as supporting improvement of Nigeria’s economy.

Okafor said: “To achieve excellence we leveraged on our investment in our world class pharmaceutical manufacturing facility to grow turnover and profit despite the challenges business environment in the country. This facility is fast growing into a hub of pharmaceutical manufacturing in West Africa with a remarkable level of capacity utilisation and efficiency. As the usage of the capacity of the factory grows, costs are now being optimised and factory is daily getting to run more efficiently and more cost effectively.”

“Our initial products have been accepted by the WHO for assessment for prequalification. So, very soon we shall be announcing the first set of Nigerian internationally prequalified products, while we continue to show deep commitment to excellence in all aspects of Good Manufacturing practices”.

“I can assure you that we keep making slow but steady progress to serve Nigerians better. We have confidence that our projects will soon materialize on the recent hinged development that Global Alliance for Vaccines and Immunisation (GAVI), the body that has been largely responsible for the funding of supply of vaccines in Nigeria will be withdrawing subsidy by 2022. This has opened the urgent need for alternative sources for funds for the supply of vaccines for routine immunisation.

“At a recent meeting of stakeholders, it was agreed that the most viable alternative would be the local manufacturing of vaccines. This would reduce cost and guaranteed availability. We shall therefore step up efforts and with the collaboration of our partners, the Federal Government, through Federal Ministry of Health we assure you that our project would soon take off for the best interest of Nigerians.”

Okafor stressed that as a company with world-class outlook, they are consistently keeping pace with international best practice, making strategic plans that can take their business to the next level.

“As you are aware, the Nigerian business environment is split into four categories of leaders, adjusters, reactors and victims. In May Baker we have reinvented the wheel to position ourselves as leaders. This is why we can confidently tell our shareholders now to expect improvement performance every year,” added.

Okafor informed that his company has been taking steps to build new class of human capacity through training, reorientation and motivational schemes for the staff members of the company.

Receive News Alerts on Whatsapp: +2348136370421

No comments yet